科學創新

華夏英泰擁有完整細胞藥物開發平臺，滿足多種臨床需求

STAR-T平臺

具有自主知識產權的合成性T細胞受體抗原受體( Synthetic TCR and Antigen Receptor), STAR-T細胞治療技術平臺。
與當前細胞治療領域常用的CAR-T技術相比，STAR-T更具有天然T細胞的特性，具有天然雙靶點，毒性低，耗竭慢，浸潤性強的特點，更有可能實現對實體瘤治療的突破。

定點整合技術

自研的定點整合技術是一種基因編輯 T細胞的顛覆性突破技術，可通過非電轉體系在指定位點插入目的基因，該技術對T細胞損傷小、易于工業化放大、成本低。
其結合STAR平臺的定點整合可代償內源TCR被敲除的缺陷，開發革命性的通用型T細胞產品。

相關新聞和發表文章

[1]A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. November 5, 2020.

了解更多ashpublications.org

[2]Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL. Hematology News. December 14, 2020.

了解更多 mdedge.com

[3]Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors.Sci Transl Med. Mar 24,2021.

了解更多 pubmed.ncbi.nlm.nih.gov

[4]A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation. ASH Meeting. December 13, 2021.

了解更多 ash.confex.com

[5]A novel CD19/CD20 dual synthetic T-cell receptor and antigen receptor (STAR) T cell therapy for refractory and relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL). EHA Library.. 06/09/2021; 324526; S118.

了解更多 library.ehaweb.org

[6] A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. American Journal of Hematology.01 May 2022

了解更多 onlinelibrary.wiley.com